Abstract：
BACKGROUND: The modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are indicators of nutritional status in cancer patients; however, the effects of baseline mGPS and PNI on the duration of administration of the ghrelin receptor agonist anamorelin, which is used to treat cachexia in patients with cancer, are unclear. This study aimed to clarify the association of mGPS and PNI with the duration of oral anamorelin administration for patients who did not have beneficial effects from anamorelin.
METHODS: The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.
RESULTS: The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.
CONCLUSIONS: Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.
METHODS: The attending physician determined the duration of oral anamorelin administration based on discontinuation due to cancer progression, poor efficacy, adverse events, or death.
RESULTS: The 12-week continuation rate of oral anamorelin was 30.4%. Univariate analysis revealed that an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 (P < .001), concurrent chemotherapy (P = .002), albumin level (P = .005), C-reactive protein level (P = .013), and a mGPS of 2 (P = .014) were statistically significant predictors of the 12-week continuation rate of oral anamorelin. In the multivariate analysis, a mGPS of 2 remained a significant risk factor, and the ECOG-PS and concurrent chemotherapy had no effect on the association between the mGPS and 12-week continuation rate of oral anamorelin.
CONCLUSIONS: Patients with a mGPS of 2, compared with mGPS of 0 or 1, are less likely to maintain oral anamorelin therapy, regardless of the ECOG-PS or concurrent chemotherapy. Therefore, it is necessary to consider initiating anamorelin administration at mGPS 0 or 1.
摘要：
背景：改良的格拉斯哥预后评分（mGPS）和预后营养指数（PNI）是癌症患者营养状况的指标；然而，基线mGPS和PNI对ghrelin受体激动剂anamorelin给药持续时间的影响，用于治疗癌症患者的恶病质，不清楚。这项研究旨在阐明mGPS和PNI与口服anamorelin给药持续时间之间的关系，这些患者对anamorelin没有有益作用。
方法：主治医师根据因癌症进展而停药的情况确定口服阿纳瑞林的持续时间，疗效差,不良事件,或死亡。
结果：口服阿纳瑞林12周延续率为30.4%。单因素分析显示，东部肿瘤协作组的表现状态（ECOG-PS）≥2（P<.001），同步化疗（P=0.002），白蛋白水平（P=0.005），C反应蛋白水平（P=0.013），mGPS为2(P=0.014)是12周口服阿纳瑞林延续率的统计学显著预测因子。在多变量分析中，mGPS为2仍然是一个重要的风险因素，ECOG-PS和同步化疗对mGPS和12周口服阿纳瑞林延续率之间的关联没有影响。
结论：与mGPS为0或1相比，mGPS为2的患者不太可能维持口服阿纳瑞林治疗，无论ECOG-PS或同步化疗。因此,有必要考虑在mGPS0或1处启动anamorelin给药。
方法：主治医师根据因癌症进展而停药的情况确定口服阿纳瑞林的持续时间，疗效差,不良事件,或死亡。
结果：口服阿纳瑞林12周延续率为30.4%。单因素分析显示，东部肿瘤协作组的表现状态（ECOG-PS）≥2（P<.001），同步化疗（P=0.002），白蛋白水平（P=0.005），C反应蛋白水平（P=0.013），mGPS为2(P=0.014)是12周口服阿纳瑞林延续率的统计学显著预测因子。在多变量分析中，mGPS为2仍然是一个重要的风险因素，ECOG-PS和同步化疗对mGPS和12周口服阿纳瑞林延续率之间的关联没有影响。
结论：与mGPS为0或1相比，mGPS为2的患者不太可能维持口服阿纳瑞林治疗，无论ECOG-PS或同步化疗。因此,有必要考虑在mGPS0或1处启动anamorelin给药。
